Insulin and sulfonylureas may need dose adjustment to prevent hypoglycemia when combined with semaglutide
Wegovy is also used to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with known cardiovascular disease and with either obesity or overweight
The FDA has issued specific warnings about compounded semaglutide products, particularly those using semaglutide sodium salt, which may contain impurities, incorrect dosages, or entirely different substances than labeled
Suspected cancer: recognition and referral NG12
doi: 10.1073/pnas.0909122107 35 NilssonNEKotarskyKOwmanCOldeB
At minimum, protein optimization and electrolyte management are essential